{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:13:57Z","timestamp":1792113237748,"version":"4.4.0"},"reference-count":136,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Oncol. Rev."],"abstract":"<jats:p>Despite increases in prevalence, many cutaneous T-cell lymphoma (CTCL) patients still lack effective and safe therapies for their disease. The most prevalent subtype, mycosis fungoides is usually managed with skin directed treatments in early stages, while advanced stages are often targeted with systemic medications. These treatments are all symptomatic except for allogeneic hematopoietic stem cell transplantation, which is associated with its own risks of relapse and potentially fatal complications. A novel class of drugs termed \u201cJAK inhibitors\u201d (JAKi) has recently been developed primarily for chronic inflammatory diseases, but there is substantial evidence of JAK\/STAT pathway overactivation also in CTCL. As of 1 December 2024, 14 JAKis have been collectively approved by the European Medicines Agency, the Food and Drug Administration and the Pharmaceutical and Medical Devices Agency of Japan. Despite some evidence from case reports, the efficacy and safety of JAKi in CTCL remains to be determined in controlled clinical trials. This review summarizes the current evidence on pathogenic JAK activation and its potential therapeutic inhibition in CTCL.<\/jats:p>","DOI":"10.3389\/or.2025.1482866","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T05:24:32Z","timestamp":1754889872000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Janus kinase inhibitors \u2013 a role for the treatment of cutaneous T-cell lymphomas?"],"prefix":"10.3389","volume":"19","author":[{"given":"Sarah E.","family":"Packer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jamaoncol.2022.3236","article-title":"Incidence trends of primary cutaneous T-cell lymphoma in the us from 2000 to 2018: a seer population data analysis","volume":"8","author":"Cai","year":"2022","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jamadermatol.2013.5526","article-title":"Changing incidence trends of cutaneous T-cell lymphoma","volume":"149","author":"Korgavkar","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002","volume":"143","author":"Criscione","year":"2007","journal-title":"Arch Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/0190-9622(92)70297-S","article-title":"Mycosis fungoides-type cutaneous T-cell lymphoma arising before 30 years of age","volume":"27","author":"Burns","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2310\/7750.2009.08091","article-title":"Mycosis fungoides in the pediatric population: report from an international childhood registry of cutaneous lymphoma","volume":"14","author":"Pope","year":"2010","journal-title":"J Cutan Med Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/s\u00e9zary syndrome: validation of the revised international society for cutaneous lymphomas\/European organisation for research and treatment of cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"JCO"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/ajh.25577","article-title":"Mycosis fungoides and S\u00e9zary syndrome: 2019 update on diagnosis, risk\u2010stratification, and management","volume":"94","author":"Hristov","year":"2019","journal-title":"Am J Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.4137\/CMO.S8536","article-title":"Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma","volume":"6","author":"Rodd","year":"2012","journal-title":"Clin Med Insights Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.clml.2012.06.010","article-title":"Age, race, sex, stage, and incidence of cutaneous lymphoma","volume":"12","author":"Wilson","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jama.1988.03410010050033","article-title":"Mycosis fungoides in the United States: increasing incidence and descriptive epidemiology","volume":"260","author":"Weinstock","year":"1988","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.clindermatol.2016.07.010","article-title":"Cutaneous lymphoma: kids are not just little people","volume":"34","author":"Ferenczi","year":"2016","journal-title":"Clin Dermatol"},{"key":"B14","year":""},{"key":"B15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3389\/fonc.2019.00645","article-title":"Antibody-directed therapies: toward a durable and tolerable treatment platform for CTCL","volume":"9","author":"Khan","year":"2019","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1001\/archderm.136.4.504","article-title":"Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients","volume":"136","author":"Van Doorn","year":"2000","journal-title":"Arch Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/archderm.1995.01690210033005","article-title":"Prognostic factors in erythrodermic mycosis fungoides and the s\u00e9zary syndrome","volume":"131","author":"Kim","year":"1995","journal-title":"Arch Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and s\u00e9zary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/j.1365-2133.2003.05698.x","article-title":"Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas","volume":"149","author":"Whittaker","year":"2003","journal-title":"Br J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.3816\/CLM.2008.s.015","article-title":"Novel therapies for cutaneous T-cell lymphomas","volume":"8","author":"Horwitz","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"B23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.21037\/cco.2018.10.03","article-title":"Allogeneic hematopoietic stem cell transplantation in advanced stage mycosis fungoides and S\u00e9zary syndrome: a concise review","volume":"8","author":"Johnson","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbmt.2019.08.019","article-title":"Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T cell lymphoma: results of a systematic review and meta-analysis","volume":"26","author":"Iqbal","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3324\/haematol.2013.098145","article-title":"Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on cutaneous lymphomas","volume":"99","author":"de Masson","year":"2014","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.21037\/cco.2018.11.03","article-title":"Update on skin directed therapies in mycosis fungoides","volume":"8","author":"Lovgren","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jaad.2020.05.043","article-title":"Response to topical corticosteroid monotherapy in mycosis fungoides","volume":"84","author":"Kartan","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1396-0296.2003.01639.x","article-title":"Treatment of patch-stage mycosis fungoides with topical corticosteroids","volume":"16","author":"Zackheim","year":"2003","journal-title":"Dermatol Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1007\/s13555-022-00831-w","article-title":"Maintenance and concomitant therapy use with chlormethine gel among patients with stage IA\/IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): a real-world evidence study","volume":"12","author":"Querfeld","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/1346-8138.16289","article-title":"Current treatment strategies and emerging therapies for cutaneous lymphoma","volume":"49","author":"Yonekura","year":"2022","journal-title":"The J Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1056\/NEJM199704103361501","article-title":"Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA)","volume":"336","author":"Stern","year":"1997","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.semradonc.2007.02.001","article-title":"Cutaneous lymphomas","volume":"17","author":"Smith","year":"2007","journal-title":"Semin Radiat Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archdermatol.2011.98","article-title":"The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides","volume":"147","author":"Navi","year":"2011","journal-title":"Arch Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3109\/0284186X.2011.585999","article-title":"Total skin electron beam therapy for cutaneous T-cell lymphoma: a nationwide cohort study from Denmark","volume":"50","author":"Lindahl","year":"2011","journal-title":"Acta Oncologica"},{"key":"B36","doi-asserted-by":"publisher","first-page":"275","DOI":"10.21873\/anticanres.16945","article-title":"Total skin electron beam therapy (TSEBT) in the management of mycosis fungoides: single institution experience","volume":"15","author":"Shouman Na","year":"2003","journal-title":"J Egypt Natl Cancer Inst"},{"key":"B37","doi-asserted-by":"publisher","first-page":"0400","DOI":"10.1523\/ENEURO.0400-18.2019","article-title":"Selective restoration of pomc expression in glutamatergic POMC neurons: evidence for a dynamic hypothalamic neurotransmitter network","volume":"6","author":"Jones","year":"2019","journal-title":"eNeuro"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/s0360-3016(97)00127-2","article-title":"Total skin electron beam therapy followed by adjuvant psoralen\/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides)","volume":"38","author":"Quiros","year":"1997","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.ijrobp.2003.08.007","article-title":"Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation)","volume":"58","author":"Ysebaert","year":"2004","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"B40","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/s0360-3016(98)00218-1","article-title":"Radiotherapy for unilesional mycosis fungoides","volume":"42","author":"Micaily","year":"1998","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"B41","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0360-3016(77)90182-1","article-title":"The rationale for curative radiotherapy in mycosis fungoides","volume":"2","author":"Hoppe","year":"1977","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1365-2133.1985.tb02340.x","article-title":"Total skin electron beam irradiation for cutaneous T-cell lymphoma (mycosis fungoides)","volume":"112","author":"Vloten","year":"1985","journal-title":"Br J Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/archderm.1996.03890350051009","article-title":"Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis","volume":"132","author":"Kim","year":"1996","journal-title":"Arch Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/0360-3016(95)00073-8","article-title":"Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy","volume":"32","author":"Wilson","year":"1995","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/s0360-3016(98)00517-3","article-title":"Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides","volume":"43","author":"Chinn","year":"1999","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"B46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1067\/mjd.2000.105510","article-title":"Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides","volume":"43","author":"Wilson","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4216098","DOI":"10.1155\/2020\/4216098","article-title":"Ultra-low-dose radiotherapy for palliation of mycosis fungoides","volume":"2020","author":"Aral","year":"2020","journal-title":"Case Rep Dermatol Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/0360-3016(94)90103-1","article-title":"Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 or 35 GY","volume":"28","author":"Jones","year":"1994","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"B49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.rpor.2013.08.008","article-title":"Clinical results of the total skin electron irradiation of the mycosis fungoides in adults. Conventional fractionation and low dose schemes","volume":"19","author":"Kazmierska","year":"2014","journal-title":"Rep Pract Oncol and Radiother"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1007\/s00066-017-1188-8","article-title":"Low-dose total skin electron beam therapy for cutaneous lymphoma: minimal risk of acute toxicities","volume":"193","author":"Kroeger","year":"2017","journal-title":"Strahlenther Onkol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e651","DOI":"10.1016\/j.ijrobp.2011.01.023","article-title":"Revisiting low-dose total skin electron beam therapy in mycosis fungoides","volume":"81","author":"Harrison","year":"2011","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"B52","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2133.1982.tb00332.x","article-title":"Cutaneous T-cell lymphoma: clinicopathological relationships, therapy and survival in ninety-two patients","volume":"107","author":"Hamminga","year":"1982","journal-title":"Br J Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000018214","article-title":"Cutaneous T cell lymphoma: update of treatment","volume":"199","author":"Zackheim","year":"1999","journal-title":"Dermatology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"adv00384","DOI":"10.2340\/00015555-3719","article-title":"Benefit\/risk ratio of low-dose methotrexate in cutaneous lesions of mycosis fungoides and sezary syndrome","volume":"101","author":"Alenezi","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"B55","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"424","DOI":"10.7150\/ijms.30154","article-title":"Histone deacetylases (HDACs) guided novel therapies for T-cell lymphomas","volume":"16","author":"Zhang","year":"2019","journal-title":"Int J Med Sci"},{"key":"B58","unstructured":""},{"key":"B59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1188\/12.CJON.195-204","article-title":"Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma","volume":"16","author":"Frye","year":"2012","journal-title":"Clin J Oncol Nurs"},{"key":"B60","unstructured":"Efficacy-labeling change with clinical data"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/imt.14.94","article-title":"Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas","volume":"6","author":"Remer","year":"2014","journal-title":"Immunotherapy"},{"key":"B62","unstructured":"Labeling-package insert"},{"key":"B63","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11864-020-00809-w","article-title":"Mycosis fungoides and sezary syndrome: updates and review of current therapy","volume":"22","author":"Kamijo","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"B64","unstructured":"Efficacy-labeling change with clinical data"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"The Lancet Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"The Lancet"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.3390\/cancers12102856","article-title":"Allogeneic hematopoietic stem cell transplantation in cutaneous T-cell lymphomas","volume":"12","author":"Dumont","year":"2020","journal-title":"Cancers"},{"key":"B68","doi-asserted-by":"publisher","first-page":"103390","DOI":"10.1016\/j.retram.2023.103390","article-title":"Are we there yet? cellular therapies for cutaneous T cell lymphoma","volume":"71","author":"Atilla","year":"2023","journal-title":"Curr Res Translational Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","article-title":"A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome","volume":"15","author":"Wu","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Duarte","year":"2010","journal-title":"J Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"780","DOI":"10.3390\/cancers16050780","article-title":"JAK inhibitors in cutaneous T-cell lymphoma: friend or foe? a systematic review","volume":"16","author":"Aldana","year":"2024","journal-title":"Cancers."},{"key":"B72","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3389\/fonc.2018.00287","article-title":"\u201cDo we know jack\u201d about JAK? A closer look at JAK\/STAT signaling pathway","volume":"8","author":"Bousoik","year":"2018","journal-title":"Front Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"a011205","DOI":"10.1101\/cshperspect.a011205","article-title":"The JAK\/STAT pathway","volume":"4","author":"Harrison","year":"2012","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduction Targeted Ther"},{"key":"B75","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B76","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1089\/jir.2014.0012","article-title":"Involvement of the janus kinase\/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis","volume":"34","author":"Benveniste","year":"2014","journal-title":"J Interferon and Cytokine Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"key":"B78","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","author":"O'Shea","year":"2014"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.3390\/cancers13081931","article-title":"Mycosis fungoides and sezary syndrome: an integrative review of the pathophysiology, molecular drivers, and targeted therapy","volume":"13","author":"Garcia-Diaz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B80","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.canlet.2013.07.037","article-title":"Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK\/STAT and Src\/FAK signaling","volume":"341","author":"Macha","year":"2013","journal-title":"Cancer Lett"},{"key":"B83","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/mc.21841","article-title":"JAK\/STAT\/SOCS-signaling pathway and colon and rectal cancer","volume":"52","author":"Slattery","year":"2013","journal-title":"Mol Carcinogenesis"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e109114","DOI":"10.1371\/journal.pone.0109114","article-title":"Astaxanthin inhibits JAK\/STAT-3 signaling to abrogate cell proliferation, invasion and angiogenesis in a hamster model of oral cancer","volume":"9","author":"Kowshik","year":"2014","journal-title":"PLoS ONE"},{"key":"B85","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.stem.2015.06.003","article-title":"Small-molecule-Driven direct reprogramming of mouse fibroblasts into functional neurons","volume":"17","author":"Li","year":"2015","journal-title":"Cell Stem Cell"},{"key":"B86","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41568-022-00537-3","article-title":"STAT proteins in cancer: orchestration of metabolism","volume":"23","author":"Li","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int Immunopharmacology"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.3324\/haematol.2015.132837","article-title":"Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma","volume":"100","author":"Perez","year":"2015","journal-title":"Haematologica"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"B90","article-title":"Committee for medicinal products for human use (CHMP): summary of opinion","year":"2024"},{"key":"B91","unstructured":"FDA-approved drugs: highlights of prescribing information\n          \n          \n          2022"},{"key":"B92","year":""},{"key":"B93","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1158\/2159-8290.CD-21-1207","article-title":"Genomic and single-cell landscape reveals novel drivers and therapeutic vulnerabilities of transformed cutaneous T-cell lymphoma","volume":"12","author":"Song","year":"2022","journal-title":"Cancer Discov"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet"},{"key":"B95","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/2159-8290.CD-12-0028","article-title":"Janus kinase 3-activating mutations identified in natural killer\/T-cell lymphoma","volume":"2","author":"Koo","year":"2012","journal-title":"Cancer Discov"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1182\/blood-2013-05-504308","article-title":"PLCG1 mutations in cutaneous T-cell lymphomas","volume":"123","author":"Vaque","year":"2014","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","first-page":"8470","DOI":"10.1038\/ncomms9470","article-title":"Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome","volume":"6","author":"Kiel","year":"2015","journal-title":"Nat Commun"},{"key":"B98","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1182\/blood-2016-02-699843","article-title":"Candidate driver genes involved in genome maintenance and DNA repair in Sezary syndrome","volume":"127","author":"Woollard","year":"2016","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Ungewickell","year":"2015","journal-title":"Nat Genet"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/bloodadvances.2020001441","article-title":"Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma","volume":"4","author":"Iyer","year":"2020","journal-title":"Blood Adv"},{"key":"B101","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/gcc.22679","article-title":"Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides","volume":"57","author":"Bastidas Torres","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/sj.leu.2403385","article-title":"In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3","volume":"18","author":"Sommer","year":"2004","journal-title":"Leukemia"},{"key":"B103","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1182\/blood-2017-02-768234","article-title":"Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E)","volume":"130","author":"Park","year":"2017","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.molonc.2011.02.003","article-title":"miRNA expression profiling of mycosis fungoides","volume":"5","author":"van Kester","year":"2011","journal-title":"Mol Oncol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.4161\/15384101.2014.965061","article-title":"Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression","volume":"13","author":"Netchiporouk","year":"2014","journal-title":"Cell Cycle"},{"key":"B109","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00281-016-0594-9","article-title":"Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover","volume":"39","author":"Krejsgaard","year":"2017","journal-title":"Semin Immunopathol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1365-2567.2007.02719.x","article-title":"Immunological decision-making: how does the immune system decide to mount a helper T-cell response?","volume":"123","author":"Kaiko","year":"2008","journal-title":"Immunology"},{"key":"B112","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00281-021-00857-w","article-title":"What does elevated TARC\/CCL17 expression tell us about eosinophilic disorders?","volume":"43","author":"Catherine","year":"2021","journal-title":"Semin Immunopathol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3390\/cancers16050861","article-title":"JAK inhibitors in cutaneous T-cell lymphoma: friend or foe? A systematic review of the published literature","volume":"16","author":"Vahabi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B114","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jdcr.2022.10.010","article-title":"A case of erythrodermic mycosis fungoides responding to upadacitinib","volume":"30","author":"Castillo","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B115","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/ddg.15325","article-title":"Severely pruritic mycosis fungoides successfully treated with upadacitinib","volume":"22","author":"Kook","year":"2024","journal-title":"JDDG: J der Deutschen Dermatologischen Gesellschaft"},{"key":"B116","doi-asserted-by":"publisher","first-page":"2050313X241231491","DOI":"10.1177\/2050313X241231491","article-title":"Cutaneous T-cell lymphoma in a JAK inhibitor patient: a case report","volume":"12","author":"Mo","year":"2024","journal-title":"SAGE Open Med Case Rep"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1182\/bloodadvances.2020001497","article-title":"Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis","volume":"4","author":"Levy","year":"2020","journal-title":"Blood Adv"},{"key":"B118","unstructured":"2021"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1182\/blood-2018-99-119944","article-title":"The novel SYK\/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in a phase 2a study in relapsed\/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"B120","unstructured":"2022"},{"key":"B121","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1182\/blood-2019-123986","article-title":"A phase 2 study of the dual SYK\/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed\/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"134","author":"Horwitz","year":"2019","journal-title":"Blood"},{"key":"B122","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"key":"B123","unstructured":""},{"key":"B124","unstructured":"2024"},{"key":"B125","unstructured":""},{"key":"B126","unstructured":"2025"},{"key":"B127","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1182\/blood-2024-206462","article-title":"Dual-targeted therapy with ruxolitinib plus duvelisib for T-cell lymphoma","volume":"144","author":"Moskowitz","year":"2024","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jdv.19426","article-title":"The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Yoon","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/all.15845","article-title":"Intrapatient comparison of atopic dermatitis skin transcriptome shows differences between tape-strips and biopsies","volume":"79","author":"Del Duca","year":"2024","journal-title":"Allergy"},{"key":"B130","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jaci.2020.05.048","article-title":"Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis","volume":"147","author":"He","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/all.14490","article-title":"Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin","volume":"76","author":"Pavel","year":"2021","journal-title":"Allergy"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3389\/fimmu.2020.01768","article-title":"Tape-strip proteomic profiling of atopic dermatitis on dupilumab identifies minimally invasive biomarkers","volume":"11","author":"He","year":"2020","journal-title":"Front Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1097\/DER.0000000000000764","article-title":"Transcriptomic profiling of tape-strips from moderate to severe atopic dermatitis patients treated with dupilumab","volume":"32","author":"Mikhaylov","year":"2021","journal-title":"Dermatitis"},{"key":"B134","doi-asserted-by":"crossref","first-page":"522","DOI":"10.6004\/jnccn.2020.0022","article-title":"NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020","volume":"18","author":"Mehta-Shah","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B135","doi-asserted-by":"crossref","first-page":"1284045","DOI":"10.3389\/fimmu.2023.1284045","article-title":"Advances in the treatment of mycoses fungoides and S\u00e9zary syndrome: a narrative update in skin-directed therapies and immune-based treatments","volume":"14","author":"Stuver","year":"2023","journal-title":"Front Immunol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1080\/10428194.2025.2455489","article-title":"Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase\/janus kinase inhibitor, in relapsed\/refractory peripheral T-cell lymphoma","volume":"66","author":"Horwitz","year":"","journal-title":"Leuk Lymphoma"}],"container-title":["Oncology Reviews"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2025.1482866\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T05:24:34Z","timestamp":1754889874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2025.1482866\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":136,"alternative-id":["10.3389\/or.2025.1482866"],"URL":"https:\/\/doi.org\/10.3389\/or.2025.1482866","relation":{},"ISSN":["1970-5557"],"issn-type":[{"value":"1970-5557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"article-number":"1482866"}}